Bisopro

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bisopro

Property Description
Active ingredient Bisoprolol fumarate
Form Film-coated tablet (Oral administration)
Pharmacological class Beta-adrenergic blocking agent (Cardioselective beta1-antagonist)
General purpose Cardiovascular system stabilization
Origin Synthetic compound
Brand Note Prescription-only (Rx)

What Type of Medicine is Bisopro?

Bisoprolol fumarate is the active ingredient in the drug Bisopro, and it belongs to the class of medications known as Beta-adrenergic blocking agents, or beta-blockers. Specifically, Bisoprolol is recognized as a highly cardioselective beta1-antagonist, meaning its primary mechanism involves selectively blocking the beta1 receptors that are found predominantly in the heart tissue. This high selectivity provides a notable differentiation, supporting its utility in patients where non-selective receptor antagonism is less desirable. Clinically, this makes the drug a preferred choice for heart-related management in certain patient groups. Bisoprolol is a synthetic compound that has been clinically recognized as a foundational therapy for maintaining cardiovascular function.

Composition, Form, and General Purpose

Bisopro is a single-ingredient product presented for oral administration typically in the form of a film-coated tablet. These tablets contain the active substance, Bisoprolol fumarate, combined with various solid pharmaceutical excipients that form the inert vehicle. The fundamental therapeutic purpose of this medication is to systematically stabilize the cardiovascular system by reducing its workload. This selective antagonism results in the heart beating with both a slower rate (negative chronotropy) and a reduced force of contraction (negative inotropy). The main effect of Bisoprolol is to decrease cardiac output and reduce the heart’s oxygen demand. This action helps ensure the heart works more efficiently and is placed under less physical stress, providing consistent circulatory control throughout the 24-hour dosing interval.

What side effects are possible with Bisopro?

Possible Side Effects and Safety Information

The information regarding the adverse effects and safety characteristics of Bisopro (Bisoprolol fumarate) is derived exclusively from official government regulatory documentation, such as the Summary of Product Characteristics (SmPC) and FDA-approved labeling.

Official Adverse Reactions by Frequency

Side effects are classified by their documented frequency in clinical trials, ranging from Very Common (occurring in ge1 in 10 patients) to Very Rare (<1 in 10,000 patients).

Frequency Examples of Adverse Reactions (by System-Organ Class)
Very Common Bradycardia (slow heart rate, noted in chronic heart failure patients).
Common Fatigue, Asthenia, Dizziness, Headache (often initial, transient symptoms), Gastrointestinal complaints (Nausea, Diarrhoea, Constipation), Feeling of coldness/numbness in the extremities.
Uncommon AV-conduction disturbances, Bronchospasm (in susceptible patients), Sleep disorders, Depression, Muscular cramps/weakness.
Rare Hepatitis, Syncope (fainting), Nightmares, Hallucinations, Reduced tear flow, Hypersensitivity reactions (e.g., rash, pruritus).

Serious Adverse Reactions and Restrictions

Official labeling documents emphasize the risk of serious cardiac events following the abrupt cessation of therapy, particularly in individuals with coronary artery disease. These events may include the exacerbation of angina pectoris, myocardial infarction, or ventricular arrhythmia. The dose must be reduced gradually over one to two weeks upon discontinuation.

Safety constraints also apply to specific conditions: Bisopro is generally contraindicated in acute heart failure, cardiogenic shock, and specific degrees of heart block. Caution is advised for patients with renal or hepatic impairment, as slower drug clearance may increase effects. Additionally, the drug may mask the signs of hypoglycemia (such as tachycardia) in diabetic patients, and may increase the sensitivity to allergens with an attenuated response to epinephrine treatment.

Overdose and Emergency Response

Overdose and when to seek help

If an overdose of Bisopro (Bisoprolol) is suspected, immediate medical attention is required. Contact a poison control center, hospital emergency department, or healthcare professional right away, even if no symptoms are present.

Signs and Symptoms of Overdose

Taking too much Bisoprolol can lead to serious physiological manifestations. The documented signs of overdose often affect the cardiovascular, respiratory, and nervous systems.

Symptoms to monitor for include:

  • Swelling of the hands, feet, ankles, or lower legs, and unusual weight gain.
  • Difficulty breathing or wheezing.
  • Dizziness, lightheadedness, or fainting.
  • Shakiness, sweating, confusion, blurred vision, or headache.
  • Extreme tiredness, weakness, or sudden hunger.

It is important to note that Bisoprolol can potentially mask the signs of low blood sugar, which may include shakiness and sweating.

Emergency Action

Call emergency services (such as 911 in the U.S. and Canada) immediately if the person who has taken too much Bisopro has:

  • Collapsed or lost consciousness.
  • Had a seizure.
  • Severe trouble breathing or can't be awakened.

Urgent medical help should be sought for any suspected overdose. Do not wait for symptoms to appear before seeking professional assistance.

Therapeutic Uses of Bisopro

Bisopro is commonly used for the long-term management of chronic cardiovascular conditions, often applied across therapeutic domains where supportive symptom management is appropriate. The medication assists with managing symptoms related to systemic imbalance and heightened physiological activity. It is generally used to address systemic high blood pressure (hypertension), chronic heart failure, and angina pectoris (chest discomfort related to heart work), as well as certain cardiac arrhythmias.


Therapeutic Benefits in Chronic Conditions

In hypertension, Bisopro is used in adults for the long-term management of elevated blood pressure, which is linked to organ-specific functional stress. This therapeutic support contributes to lowering pressure readings, playing a role in managing symptoms that create noticeable physiological strain. For patients dealing with chronic heart failure, the medication may be part of symptomatic management during stable phases. Applied in this context, it helps ease the overall symptom load and supports general well-being during symptomatic periods.

It is also relevant for easing chest discomfort or pain (angina) associated with coronary artery disease and helps address symptoms of certain cardiac arrhythmias, such as heart palpitations. The treatment helps address symptom clusters that may become intense or disruptive, assists with maintaining functional stability, and contributes to improved day-to-day comfort.



Quick Fact: Relief for Cardiac Overwork Bisopro helps address symptom clusters that may become intense or disruptive. This provides supportive relief when symptoms interfere with routine activities and contributes to a greater sense of stability during symptomatic periods.


Eligibility and Restrictions for Use

Official Population Eligibility for Bisopro

Regulatory documents define the population eligible to use Bisopro (Bisoprolol fumarate) primarily as Adults for its approved indications. Eligibility is strictly limited by cardiac status, pre-existing conditions, organ function, and age.

Category Official Regulatory Classification
Populations for whom use is contraindicated Patients with acute heart failure, cardiogenic shock, marked sinus bradycardia, second or third degree AV block, severe bronchial asthma, or severe peripheral arterial occlusive disease.
Age-related eligibility rules Pediatric: Use is not recommended; safety and effectiveness have not been established in children and adolescents under 18. Geriatric: Approved for use with no routine dose adjustment unless severe organ dysfunction is present.
Condition-specific eligibility rules Severe Renal/Hepatic Impairment: Use with caution; the dose should generally not exceed 10 mg once daily for hypertension or angina.
Pregnancy and lactation eligibility status Pregnancy: Use is conditional, recommended only if potential benefit justifies potential risk to the fetus. Lactation: Use with caution, as it is unknown if the drug is excreted in human milk.

Connection to the overall eligibility profile Official regulatory documents define the eligible population for this drug by prohibiting use in states of acute cardiac instability and severe pulmonary disease, and by setting restrictions for use in populations with established organ impairment or insufficient data, such as the pediatric age group.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Bisoprolol fumarate, the active ingredient in Bisopro, focuses on combination restrictions and risk classifications as defined in official regulatory documents. Certain combinations are explicitly contraindicated.

Documented Combination Restrictions

Classification Interacting Agent Official Documented Outcome
Contraindicated Floctafenine, Sultopride Risk of impeding cardiovascular compensatory reactions and increased risk of ventricular arrhythmia (SmPC).
Use with Caution Calcium Antagonists (Verapamil/Diltiazem type) Additive negative effects on heart contractility and atrio-ventricular conduction (FDA, SmPC).

Pharmacodynamic and Exposure Interactions

Co-administration with other beta-blocking agents, including topical eye drops, should be avoided due to the potential for additive systemic effects. The use of Digitalis glycosides can increase the risk of bradycardia through slowed atrioventricular conduction. For patients taking Insulin or oral anti-diabetic drugs, Bisoprolol may enhance the blood sugar-lowering effect and can mask the symptoms of hypoglycemia, specifically fast heart rate.

Rifampin (an enzyme inducer) increases the metabolic clearance of Bisoprolol, resulting in a shortened elimination half-life. Conversely, the official labeling notes that Bisoprolol's absorption is unaffected by food intake and that it is not metabolized by the CYP2D6 enzyme.

Administration Sequencing

When discontinuing therapy that includes a centrally acting antihypertensive drug, such as Clonidine, Bisoprolol must be withdrawn several days prior to the central antihypertensive to mitigate the risk of rebound hypertension, as stated in prescribing information.

Mechanism of Action

Selective Attenuation of Sympathetic Drive

Bisoprolol's primary mechanism involves selective, competitive antagonism of the beta1-adrenoceptors, which are concentrated in the cardiac muscle and the heart's electrical conduction system. By blocking these receptors, the drug directly suppresses the stimulatory effects of the catecholamines norepinephrine and epinephrine from the Sympathetic Nervous System. This molecular action initiates a cascade that leads to a reduction in the electrical firing rate of the sinoatrial node, producing a negative chronotropic effect.

Modulation of Cardiac Contraction and Workload

The beta1 blockade dampens the intracellular signaling required for forceful muscle contraction, resulting in a negative inotropic effect (reduced force of contraction) in the heart muscle cells. This domain of action, which slows the rate and reduces the force, decreases the functional parameters of the heart, resulting in a reduction of Myocardial Oxygen Consumption. This mechanism acts as an antagonist to sympathetic tone, altering the physiological response pathway.

Neurohumoral System Interference

Beyond the heart, the drug engages mechanisms that influence regulatory feedback loops by blocking beta1 receptors in the kidneys’ juxtaglomerular apparatus. This action inhibits the release of Renin, the enzyme that initiates the Renin-Angiotensin-Aldosterone System (RAAS) cascade. This pathway interference attenuates the subsequent effects mediated by the RAAS, including reduced fluid retention and vasoconstriction, which results in a lowering of systemic arterial pressure.

Dosage and Administration Information

Bisoprolol fumarate (Bisopro) is administered strictly via the oral route as a film-coated tablet. The medication is used on a once-daily schedule, typically taken in the morning. The tablets must be swallowed whole with liquid and may be taken independently of meals, meaning administration is flexible regarding food intake. The tablets should not be crushed or chewed, maintaining the integrity of the formulation.


Standard adult dosing for conditions like hypertension and stable angina usually begins at 5 mg once daily, with the option to increase the dose, but not exceeding the maximum daily dose of 20 mg. For the management of stable chronic heart failure, the process is characterized by a structured approach. Treatment starts with a very low initial dose of 1.25 mg once daily and is then gradually titrated. This involves doubling the dose in weekly or bi-weekly steps, provided the patient is stable, up to a target maximum of 10 mg once daily.

Special administration limits apply to certain patient groups. The maximum dose must not exceed 10 mg once daily for patients with severe hepatic or renal impairment. Furthermore, the protocol for discontinuing Bisopro is critical: treatment is not stopped suddenly. Instead, the dose is slowly and progressively reduced (tapered) over approximately one to two weeks.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Acute and Chronic Pain Management

Research has investigated the effects of Drug A in studies of both acute and chronic pain. The primary focus in clinical trials evaluated whether the compound influences inflammation, and whether this is related to a change in the sensation of pain. One Phase III trial reported a change in patient-reported pain scores in participants with acute post-operative pain, with onset of action evaluated against placebo. The trial investigated a specified dosing schedule in adults aged 18-65.

Neuropathic Pain

Another study compared outcomes for Drug A versus Drug B in chronic neuropathic pain. This study was a 6-month, randomized, controlled trial involving 400 participants. The long-term study examined whether pain was influenced over 12 months.

The characteristics of this compound were studied in most adult patients participating in the trials. The study findings also included an evaluation of administration alongside physical therapy.

Combination Therapy

The combination of Drug A and Drug C was evaluated with mobility as a primary endpoint compared to Drug A alone in patients with osteoarthritis. This analysis looked at changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores. Research on the use of beta-blockers in combination with other agents for joint pain remains an area of ongoing investigation. Studies have explored whether the use of this class of compounds is associated with changes in the frequency or severity of reported joint pain and the requirement for other analgesics in some populations.

Frequently Asked Questions (FAQ)

Common questions about Bisopro (FAQ)

Q: How long does it typically take for Bisopro to reach its full effect on blood pressure?

Official documents indicate that the medicine starts to lower blood pressure within approximately two hours of taking the dose. However, for chronic conditions like hypertension, the full therapeutic benefit may take longer to develop. Official documents indicate that the full therapeutic effect may take between two and six weeks to develop.

Q: What types of over-the-counter pain relievers might interact with Bisopro?

Official drug information indicates that some common over-the-counter pain relievers, specifically Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen, can interact with Bisopro. These agents may reduce the blood pressure-lowering effect of the medicine. This type of potential interaction is noted when these agents are used at the same time.

Q: Can Bisopro be prescribed for conditions other than high blood pressure?

Yes, official regulatory labeling states that Bisopro is approved for the treatment of high blood pressure (hypertension) as well as other chronic conditions. Specifically, it is also indicated for the management of stable chronic angina pectoris and for stable chronic heart failure, typically used in combination with other medicines.

Q: Are the initial side effects of Bisopro usually temporary?

Regulatory documents indicate that some of the common initial unwanted effects, such as dizziness and headache, are typically mild. These initial symptoms are often transient, and regulatory information notes they may disappear within one to two weeks of beginning treatment.

Q: Is Bisopro classified as a 'blood thinner' or an anticoagulant?

Bisopro is officially classified as a beta-adrenergic blocking agent, which is commonly called a beta-blocker. This medication works on the heart to reduce workload. Official documentation does not classify Bisoprolol as an anticoagulant, meaning it is not considered a "blood thinner."

Q: What is the difference between Bisopro and other types of beta-blockers?

Official literature describes Bisopro as a highly cardioselective \beta1-antagonist. This means its mechanism primarily involves selectively blocking the \beta1 receptors, which are predominantly located in the heart. Its selective action on the \beta1 receptors in the heart is a feature that distinguishes it from non-selective beta-blockers.

Q: Why is Bisopro sometimes used to treat heart failure when it slows the heart rate?

In the management of heart failure, Bisopro is used in combination with other drugs. This action is intended to reduce the heart's workload and help the heart muscle pump blood around the body more efficiently. The goal is to ensure consistent circulatory control and reduce the heart's oxygen demand.

Q: Are there any long-term health concerns or side effects associated with Bisopro use over several years?

Bisopro is generally considered a long-term treatment for its approved indications. Official documentation indicates that regular medical monitoring is important for patients receiving long-term therapy. This is essential to ensure the medication remains effective and to check for potential changes, such as unexpected weight gain or signs of the underlying condition worsening.

Q: Can taking Bisopro lead to weight gain?

Official documentation lists weight gain as a less common side effect. In patients using Bisopro for heart failure, unexpected or rapid weight gain is a symptom that may indicate a worsening of their underlying heart condition. Official information suggests checking with a healthcare provider if this or other changes occur.

Q: Is there a known link between Bisopro and joint or muscle pain?

Regulatory information documents that muscular weakness and muscle cramps are uncommon side effects associated with Bisopro. Additionally, other reports include myalgia (muscle pain), arthralgia (joint pain), and general limb pain. These effects have been documented in official data.

Q: Does Bisopro have an effect on sexual function or libido?

Official product information notes that effects on sexual function are documented in some cases. Erectile dysfunction or potency disorders are listed as a rare side effect in clinical trial data. There are also reports indicating decreased libido.

Q: Does the official labeling mention interactions with stimulants or cold/flu decongestants?

Official warnings caution about combining Bisopro with certain sympathomimetic agents, which are often found in stimulants and over-the-counter cold and flu decongestants. These combinations can potentially lead to an increase in blood pressure and may negate the intended blood pressure-lowering effect of Bisopro.

Q: How long does the drug stay in a patient's system after the last dose is taken?

The elimination half-life, which refers to the time it takes for half of the drug to be removed from the bloodstream, is typically ten to twelve hours. This characteristic is the pharmacological basis for the medicine's common once-daily dosing schedule.

Q: What advice is given about driving or operating heavy machinery while taking Bisopro?

Regulatory warnings state that Bisopro may cause side effects such as fatigue or dizziness, especially when first starting treatment or changing dose. If a patient experiences these specific effects, warnings state that activities such as driving or operating heavy machinery may need to be avoided.

Q: What research has been done on Bisopro's effects on cholesterol or triglyceride levels?

Regulatory information lists increased triglycerides and increased liver enzymes as rare findings from investigations into the medication’s metabolic effects. This indicates these parameters have been studied during clinical development.

Q: Are there any specific research themes about the use of Bisopro in diverse populations?

Pharmacokinetic studies have examined how the drug behaves in the body of various patient groups. This research has included specific populations, such as those with chronic heart failure or those with impaired liver or kidney function.

Q: What should a patient do if they accidentally take more than their prescribed Bisopro dose?

Official patient information lists symptoms of overdose, which can include a very slow heart rate, severe difficulty breathing, or significant dizziness. In the event an overdose is suspected, official information states that immediate medical attention is necessary.

Q: Can Bisopro be taken 'as needed' for high anxiety or performance stress?

Regulatory labeling describes Bisopro's use for chronic conditions such as hypertension, angina, and heart failure. The approved dosing schedule requires once-daily, long-term use, and it is not described for 'as needed' use in official product information.

Q: Is Bisopro a medication that is usually taken for the rest of one's life?

Treatment for its approved chronic cardiovascular conditions, particularly heart failure, is generally considered a long-term commitment. Official warnings emphasize that this medication should not be stopped abruptly but must be gradually reduced under medical guidance.

Q: What is the usual time of day for taking Bisopro?

The medication is typically taken once a day in the morning. Some patient materials suggest that the very first dose may be taken at bedtime. This is sometimes mentioned as a way to assess for any initial dizziness or lightheadedness that might occur.

Q: Can Bisopro be taken by people with certain lung conditions like asthma or COPD?

Bisopro is officially contraindicated for patients with severe bronchial asthma. Caution is advised for those with less severe asthma or chronic lung disease. Official information notes that a patient with these conditions may require concomitant bronchodilating therapy if using Bisopro.

Q: How often are follow-up visits usually needed when starting Bisopro?

The FDA label emphasizes the importance of regular medical visits for checking progress and monitoring the medication's effectiveness. For patients beginning treatment for heart failure, there is a highly structured phase of dose changes that requires close observation and frequent monitoring.

How should Bisopro be stored and disposed of?

Storage and Disposal Requirements

Bisoprolol fumarate tablets must be stored according to official regulatory specifications to maintain product quality.

Mandatory Storage Conditions

The medicine requires storage at a temperature not above 30°C (86°F), and certain presentations, such as opened bottles, may require storage below 25°C (77°F). It is mandatory to keep the product from freezing and protect it from light and moisture. The tablets must be stored in the original container to maintain these protection standards.

  • Child Safety: Always store Bisoprolol out of the sight and reach of children.
  • Stability Constraint: If using an opened bottle, the product must be discarded after a shelf life of 6 months.

Disposal of Unused Product

Any expired or unused Bisoprolol tablets should be disposed of strictly in accordance with local requirements. Patients must be instructed to inquire with a healthcare professional regarding local collection programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bisopro found in:

A-Z Index: